Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to -$78.2 million.

  • Tg Therapeutics' Cash from Financing Activities fell 15819.24% to -$78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$96.9 million, marking a year-over-year decrease of 17196.17%. This contributed to the annual value of $128.5 million for FY2024, which is 7677.88% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Cash from Financing Activities is -$78.2 million, which was down 15819.24% from -$6.4 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Cash from Financing Activities high stood at $134.5 million for Q3 2024, and its period low was -$78.2 million during Q3 2025.
  • Its 5-year average for Cash from Financing Activities is $8.0 million, with a median of $10000.0 in 2024.
  • As far as peak fluctuations go, Tg Therapeutics' Cash from Financing Activities skyrocketed by 3474962.96% in 2023, and later crashed by 60710000.0% in 2024.
  • Tg Therapeutics' Cash from Financing Activities (Quarter) stood at $56.0 million in 2021, then tumbled by 99.91% to $49000.0 in 2022, then tumbled by 102.04% to -$1000.0 in 2023, then tumbled by 607100.0% to -$6.1 million in 2024, then crashed by 1188.57% to -$78.2 million in 2025.
  • Its last three reported values are -$78.2 million in Q3 2025, -$6.4 million for Q2 2025, and -$6.1 million during Q1 2025.